Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer

Journal of the Medical Association of Thailand

Volumn 83, Issue 5, 2000, Pages 549-553

  Thongprasert, Sumitra ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Chemotherapy; GM CSF; Small cell lung cancer

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOTENSION; LUNG SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 0033914075     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Thatcher N, Lind M, Stout R, et al. Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for "limited" stage small cell carcinoma of the bronchus. Br J Cancer 1989;60:98-101.
2. Smith IE, Perren TJ, Ashley SA, et al. Carboplatin, etoposide and ifosfamide as intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1990;8:899-905.
3. Sculier JP, Klastersky J. High-Dose chemotherapy of small-cell lung cancer. In H.H. Hansen (ed) Basic and Clinical Concepts of Lung Cancer Boston. Kluwer Academic publishers, 1989;259-74.
4. Thatcher N. Haematopoietic growth factors and lung cancer treatment. Thorax 1992;47:119-26.
5. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, (first of two parts) The New England Journal of Medicine 1992;237:28-35.
6. Grant SM, Heel RC. Recombinant granulocyte macrophage colony-stimulating factor (rGM-CSF). Drugs: 1992;43:516-60.
7. Haveman K, Klausmann M, Wolf M, et al. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer. Cancer Res Clin Oncol 1991;117:203-7.
8. Green JA, Trillet VN, Maregold C. R-metHuG-CSF (G-CSF) with CDE chemotherapy (CT) in small cell lung cancer (SCLC) interim results from a randomized, placebo controlled trial [abstract]. Proc Am Soc Clin Oncol 1991;10:243.
9. Bunn PA, Crowley J, Hazuka M, Trolley R. Livingston R. The role of GM-CSF in limited stage SCLC: A randomized phase III study of the South-West Oncology Group (SWOG). Proc Am Soc Clin Oncol 1992;11:292.
10. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991;325:164-70.
11. Luikart SD. MacDonald M, Herzan D, et al. Ability of daily or twice daily granulocyte macrophage colony stimulating factor (GM-CSF) to support dose escalation of etoposide (VP-16) and carboplatin (CBDCA) in extensive small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1991;10:242.
12. Prendiville J, Lorigan P, Hicks F, et al. Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. Eur J Cancer 1994;14:2085-90.
13. Calvert AH. Dose optimisation of carboplatin in adults. Anticancer Res 1994;14:2273-8.
14. Boni C, Cocconi G, Bisagni G, et al. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. Cancer 1989;63:638-42.
15. Medical Research Council, Lung Cancer Working Party. A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). (II) Quality of Life. Br J Cancer 1993;68:1157-66.